Linda Huguelet

Diagnosed with myeloma in 2010, Linda today co-leads the Chattanooga Multiple Myeloma Networking Group, alongside her husband. Linda will be attending the ASH Annual Meeting for the fith time. She recently participated in a CAR-T Patient Advocacy Forum hosted by Celgene and she’ll add CAR-T therapies to the things she’s most excited to learn about at the ASH conference.  Maintenance therapies, updates on the approved monoclonal antibodies, and new emerging monoclonal antibody treatments will also be a focus for her.

Follow Linda on Twitter

Back To ‘Normal’ Life

Linda Huguelet |

Well, it’s 5:00 a.m. PT, although I keep telling myself that’s 8:00 a.m. ET, so it doesn’t seem so early. I’m at the San Diego airport waiting for my flight back home from the 2018 American Society of Hematology (ASH) annual meeting and exposition. It has been four, long, intense days of being totally immersed […]

We’ve Come a Long Way and There’s No End in Sight

Linda Huguelet |

Each year at the American Society of Hematology (ASH) annual meeting, I’ve been overwhelmed by the amount of research underway to bring new treatments and hopefully a cure to multiple myeloma patients. Thankfully, this year is no different; however, last night I was reminded just how far we’ve come in a relatively short period of […]

Expertise Shared with Community Hematologists

Linda Huguelet |

The 60th Annual American Society of Hematology (ASH) meeting officially kicked off on Saturday, but the action got under way on Friday. This day was reserved for symposiums that provide continuing education for ASH attendees. The International Myeloma Foundation’s (IMF) symposium this year was Dr. Brian G. M. Durie, Chairman of the IMF, led the […]

What’s Your Next Move?

Linda Huguelet |

As the 60th Annual American Society of Hematology (ASH) meeting approaches, I’m thrilled to join the International Myeloma’s (IMF) team of patient representatives for the 6th time. Each year, I learn more and more and am ever encouraged by the continued passion shown by the researchers. Myeloma may be a rare cancer, but you’d never […]